Metastatic maganin kansar mahaifa yanzu an amince da shi

A KYAUTA Kyauta 7 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

A yau sanofi-aventis Canada Inc. (Sanofi) ya sanar da amincewar Libtayo® (cemiplimab) don kula da tsofaffi marasa lafiya da ciwon daji na mahaifa waɗanda suka ci gaba a kan ko bayan da aka yi amfani da su na platinum na chemotherapy da kuma waɗanda ke buƙatar ƙarin tsarin tsarin magani don magance maimaitawa ko metastatic. cuta. Amincewar ta dogara ne akan Nazari na Cemiplimab na Mataki na 3 EMPOWER-Cervical 1 a cikin Manya Tare da Ciwon Sankara (NCT03257267). Gwajin, wanda shine mafi girman gwajin asibiti mafi girma a cikin ciwon daji na mahaifa mai ci gaba, ya haɗa da marasa lafiya da ke da maimaitawa ko ciwon daji na mahaifa wanda tarihinsa ya kasance ko dai squamous cell carcinoma ko adenocarcinoma. An keɓance mahalarta don karɓar ko dai cemiplimab ko zaɓin chemotherapy na mai binciken. Babban abin ƙarshe na gwajin shine gaba ɗaya tsira.             

Mark Surka, Ph.D, Shugaban Likitan Oncology, Sanofi Kanada: "Yayin da adadin ciwon sankara na mahaifa a Kanada yana godiya ga raguwa, saboda tasirin maganin rigakafin HPV don hana cutar sankarar mahaifa daga formingiii, Kanada har yanzu tana ganin 1400. matan da ke fama da wannan cuta a kowace shekara kuma suna buƙatar zaɓuɓɓukan magani. Muna alfahari da kawowa Libtayo amincewa ga matan da suka kamu da cutar sankarar mahaifa ko kuma masu saurin kamuwa da cutar kansa, da kuma kwararrun likitocin da ke kula da su.”

Alamu ta huɗu ga Libtayo a cikin wahalar magance cututtukan daji

Tare da sanarwar yau, yanzu an amince da Libtayo azaman zaɓi na rigakafi don cututtukan daji guda huɗu:

•            A watan Afrilun 2019, Libtayo ta zama zaɓi na farko na rigakafi a Kanada ga manya masu fama da ƙanƙara ko ci gaban cutaneous squamous cell carcinoma (CSCC) waɗanda ba 'yan takara ba ne don aikin tiyatar warkewa ko radiation na warkewa.

•           A cikin Oktoba 2021, an faɗaɗa samuwar Libtayo don haɗa manya masu fama da ciwon huhu mara ƙanƙanta da ke bayyana PD-L1 a cikin ≥ 50% na ƙwayoyin tumor (Tumour Proportion Score [TPS] ≥ 50%), kamar yadda ingantaccen ya ƙaddara. gwajin, ba tare da EGFR, ALK ko ROS1 aberrations waɗanda suka sami ci gaba NSCLC a cikin gida waɗanda ba 'yan takarar neman aikin tiyata ba ko tabbataccen chemoradiation, ko metastatic NSCLC.

•           Haka kuma a cikin Oktoba na 2021, an amince da Libtayo don kula da manya masu fama da ciwon daji na basal cell carcinoma (BCC) a baya da aka yi musu magani tare da mai hana hanyar bushiya (HHI).

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...